Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

MBX Biosciences Announced Once-weekly Canvuparatide Achieved The Primary Endpoint With Statistical Significance In Its Phase 2 Avail Trial

Author: Benzinga Newsdesk | September 22, 2025 07:03am

Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE)
Positive findings in bone and kidney biomarkers
All patients completed the 12-week Avail trial and 94% entered the OLE
Once-weekly canvuparatide was generally well tolerated, with no treatment-related serious adverse events or discontinuations during the 12-week trial
Preparation underway to initiate Phase 3 trial in 2026

Posted In: MBX